Take heed, ye who reposition your proteomics companies for drug discovery! A panel representing investors, patent law experts, and companies assembled by the Consul General of Sweden earlier this month in New York advised — among other things — that investors aren’t convinced such a turnabout in business plan will necessarily lead to profits.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.